This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
From July to August 2025, about one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research published in Morbidity and Mortality Weekly Report.
Samantha L. Pierce, M.P.H., from the CDC in Atlanta, and colleagues examined GLP-1 RA medication use among U.S. adults using data collected from the CDC Rapid Surveys System from July to August 2025.
In addition to the adults reporting taking a GLP-1 RA medication during the past year, about one in five GLP-1 RA users reported using a compounded version; these versions have not been reviewed by the U.S. Food and Drug Administration for safety, effectiveness or quality before marketing. About two in five GLP-1 RA users reported modification of medication use from the way it was prescribed, with barriers to prescribed use including cost and availability.
"Modifications in GLP-1 medication use reflect, in part, responses to cost- and access-related challenges," the authors write. "Future research could evaluate the implications of real-world medication use, including dose and frequency adjustments, on safety and effectiveness."
Samantha L. Pierce et al., Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025, MMWR. Morbidity and Mortality Weekly Report (2026). DOI: 10.15585/mmwr.mm7544a1
Source link







